Who was that masked man? Court protects anonymity of Internet users

David Elder -

In the latest chapter in a $6 million defamation suit by a former mayor, an Ontario court has refused to order the disclosure of the identities of three individuals who used pseudonyms to post to an online forum.

The case of Morris v. Johnson should provide some comfort to those who post commentary anonymously, while serving as a cautionary tale to plaintiffs seeking to get behind the pseudonyms of their critics and detractors.

Continue Reading...

Cloud computing and Canadian federally regulated financial institutions

Wesley Ng and Stuart Carruthers  -

Cloud computing has grown significantly in the last few years. A Gartner Executive Program survey of more than 2,000 Chief Information Officers (CIOs), representing 50 countries and 38 industries, found that cloud computing is the number one technology priority for 2011. Fully 43% of the CIOs expected that a majority of their IT will be running “in the cloud” within four years. In its updated June 2011 forecast of Information Technology spending, Gartner stated that cloud computing expenditures are likely to rise by 16-20% per year through 2015, representing 4% of global IT spending by the end of that period. Richard Gordon, research vice president at Gartner, noted that expenditures for cloud computing services grew four times faster than overall IT spending.

Continue Reading...

Google case raises questions about the security of unencrypted Wi-Fi signals

Late last month, the U.S. District for the Northern District of California denied Google’s motion to dismiss a putative class action alleging that the company accessed and used data transmitted through unencrypted Wi-Fi signals (Re Google Inc. Street View Electronic Communications Litigation). Google acquired the data through its Google Street View program, which relied on specially designed Google Street View vehicles to acquire 360° panoramic images of streets across the United States, Canada and other countries. These Google Street View vehicles also featured advanced technology that allowed them to access and store data transmitted through unencrypted Wi-Fi signals.

Ultimately, Google’s motion to dismiss the Plaintiffs’ claims that it violated the federal Wiretap Act was denied. Of particular interest was the court’s interpretation of the statute with respect to Wi-Fi signals. While the Wiretap Act prohibits intentionally intercepting certain electronic communication, the statute provides an exemption for communications that are “readily accessible to the general public”. In considering the applicable provision, which predates the ubiquity of wireless internet technology, the Court compared Wi-Fi technology to that of cellular phones. Specifically, while both use radio waves to transmit communication, both are intended to be private. Ultimately, therefore, the Court found that the plaintiffs’ pleading supported a claim that communications sent via Wi-Fi technology were not “readily accessible to the general public”.

Google quickly indicated that it will appeal the ruling. The widespread use of unencrypted Wi-Fi signals ensures that this case will be closely watched as it progresses.

Federal Court of Appeal refuses to set aside prohibition order even though untrue material allegations had been made in the invalid patent at issue

A recent decision of the Federal Court of Appeal represents a blow to generic pharmaceutical companies in their quest to seek compensation for the period of time that they were precluded from entering the market with a generic version of a drug as a result of an invalid patent and lengthy proceedings under the Patented Medicines (Notice of Compliance) Regulations (NOC Regulations).

In this case, although Pfizer was successful in thwarting ratiopharm’s initial attempt to invalidate Canadian Patent No. 1,321,393 (the ‘393 Patent) under the regime of the NOC Regulations, ratiopharm was subsequently successful in a second “kick at the can” by invalidating the ‘393 Patent in an impeachment action (as reported in a previous post), which allowed ratiopharm to market its generic version of Pfizer’s drug NORVASC (amlodipine besylate).

Continue Reading...